JP2022536424A - 置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用 - Google Patents

置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用 Download PDF

Info

Publication number
JP2022536424A
JP2022536424A JP2021573899A JP2021573899A JP2022536424A JP 2022536424 A JP2022536424 A JP 2022536424A JP 2021573899 A JP2021573899 A JP 2021573899A JP 2021573899 A JP2021573899 A JP 2021573899A JP 2022536424 A JP2022536424 A JP 2022536424A
Authority
JP
Japan
Prior art keywords
methyl
pyrazolo
phenyl
pyridine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536424A5 (cg-RX-API-DMAC7.html
Inventor
ヒスコック,アフトン
ステーン,ブライス
クロビアン,クリスタ
ゲリン,クリスティーン
サマント,アンドリュー
エー. リタヴィック,マイケル
ドヴォラック,カート
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2022536424A publication Critical patent/JP2022536424A/ja
Publication of JP2022536424A5 publication Critical patent/JP2022536424A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021573899A 2019-06-14 2020-06-12 置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用 Pending JP2022536424A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861665P 2019-06-14 2019-06-14
US62/861,665 2019-06-14
PK349/2020 2020-06-03
PK34920 2020-06-03
PCT/EP2020/066384 WO2020249785A1 (en) 2019-06-14 2020-06-12 Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators

Publications (2)

Publication Number Publication Date
JP2022536424A true JP2022536424A (ja) 2022-08-16
JP2022536424A5 JP2022536424A5 (cg-RX-API-DMAC7.html) 2024-02-26

Family

ID=73781827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573899A Pending JP2022536424A (ja) 2019-06-14 2020-06-12 置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用

Country Status (21)

Country Link
US (2) US11530210B2 (cg-RX-API-DMAC7.html)
EP (1) EP3982958A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536424A (cg-RX-API-DMAC7.html)
KR (1) KR20220024512A (cg-RX-API-DMAC7.html)
CN (1) CN114007610A (cg-RX-API-DMAC7.html)
AU (1) AU2020291188A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025141A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143276A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003257A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016860A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210615A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000250A (cg-RX-API-DMAC7.html)
EC (1) ECSP21090450A (cg-RX-API-DMAC7.html)
IL (1) IL288858A (cg-RX-API-DMAC7.html)
JO (1) JOP20210330A1 (cg-RX-API-DMAC7.html)
MA (1) MA56183A (cg-RX-API-DMAC7.html)
MX (1) MX2021015503A (cg-RX-API-DMAC7.html)
PE (1) PE20220806A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112405VA (cg-RX-API-DMAC7.html)
TW (1) TW202115054A (cg-RX-API-DMAC7.html)
WO (1) WO2020249785A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
CN114149425A (zh) * 2021-11-16 2022-03-08 上海应用技术大学 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100057433A (ko) * 2008-11-21 2010-05-31 한국화학연구원 신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2016523259A (ja) * 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. 新規の二環式ブロモドメイン阻害剤
WO2018067786A1 (en) * 2016-10-06 2018-04-12 Janssen Pharmaceutica Nv Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators
JP2018520170A (ja) * 2015-07-09 2018-07-26 ヤンセン ファーマシューティカ エヌ.ベー. 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
EP1434865A2 (en) 2001-07-24 2004-07-07 Genset S.A. Variants and exons of the glyt1 transporter
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
AU2005214375A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
US20110053951A1 (en) 2008-03-27 2011-03-03 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
DK2308877T3 (da) 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
PL2570415T3 (pl) 2011-09-19 2016-01-29 Sanofi Sa N-[4-(1H-pirazolo[3,4-b]pirazyn-6-ylo)-fenylo]-sulfonamidy i ich zastosowanie jako farmaceutyki
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
JP6612751B2 (ja) 2013-07-31 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
PT3180315T (pt) 2014-08-15 2020-05-27 Janssen Pharmaceuticals Inc Pirazoles
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
CN110831593A (zh) 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100057433A (ko) * 2008-11-21 2010-05-31 한국화학연구원 신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2016523259A (ja) * 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. 新規の二環式ブロモドメイン阻害剤
JP2018520170A (ja) * 2015-07-09 2018-07-26 ヤンセン ファーマシューティカ エヌ.ベー. 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
WO2018067786A1 (en) * 2016-10-06 2018-04-12 Janssen Pharmaceutica Nv Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHROVIAN, C. C. ET AL.: "1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators", ACS MEDICINAL CHEMISTRY LETTERS, vol. 10(3), JPN6024032422, 2019, pages 261 - 266, ISSN: 0005529620 *
長瀬博, 最新 創薬化学 上巻,株式会社テクノミック, JPN6024032423, 1998, pages 243 - 248, ISSN: 0005529621 *

Also Published As

Publication number Publication date
MA56183A (fr) 2022-04-20
KR20220024512A (ko) 2022-03-03
WO2020249785A1 (en) 2020-12-17
CR20210615A (es) 2022-01-31
CO2021016860A2 (es) 2022-01-17
JOP20210330A1 (ar) 2023-01-30
US20210017169A1 (en) 2021-01-21
AU2020291188A1 (en) 2022-01-20
CN114007610A (zh) 2022-02-01
US20230045960A1 (en) 2023-02-16
DOP2021000250A (es) 2022-03-31
CA3143276A1 (en) 2020-12-17
SG11202112405VA (en) 2021-12-30
MX2021015503A (es) 2022-04-20
PE20220806A1 (es) 2022-05-20
IL288858A (en) 2022-02-01
CL2021003257A1 (es) 2022-08-19
US11530210B2 (en) 2022-12-20
EP3982958A1 (en) 2022-04-20
ECSP21090450A (es) 2022-01-31
TW202115054A (zh) 2021-04-16
BR112021025141A2 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
JP7369743B2 (ja) 置換4-アザインドール及びglun2b受容体調節因子としてのそれらの使用
US11530210B2 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
CN110062761B (zh) 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途
JP5759470B2 (ja) オレキシン受容体調節因子としての二置換オクタヒドロピロロ[3,4−c]ピロール
RU2672583C2 (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
US11161846B2 (en) Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
JP2022536773A (ja) 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用
JP2022538774A (ja) ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用
US20220274984A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
EA046270B1 (ru) ЗАМЕЩЕННЫЕ ГЕТЕРОАРОМАТИЧЕСКИЕ ПИРАЗОЛОПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GluN2B
HK40067297A (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250218